FDA panel discusses risk‑based subcategorization to apply BCS Class 3 principles to some BCS Class 4 generics

A panel of Food and Drug Administration scientists described a proposed, risk‑based framework for evaluating BCS Class 4 generic drugs that would subcategorize products by their primary limiting factor and, in some cases, allow use of evaluation principles developed for BCS Class 3 drugs.

Ging Xiao, a panelist and researcher, said the framework "leveraged scientific foundations" from FDA work and that a tiered subcategorization could identify BCS Class 4 drugs with permeability limitations that "behave like the permeability‑limited BCS class 3 drugs." Xiao cited a case study in which a product with "borderline low solubility and moderate high permeability" behaved like a permeability‑limited BCS 3 drug, and said the approach would allow applying established principles "more precisely rather than treating all the BCS 4 drugs same."

The proposal aims to replace a blanket assumption that all BCS Class 4 products are equally unpredictable. "Our framework provides the scientific rationale and the systemic approach that was not covered in the guidance," Xiao said, adding that the approach would identify whether a product's primary limitation is solubility, permeability or both and focus evaluation on that factor.

Panelists and questioners pressed on regulatory acceptance and scope. When asked how the framework addresses an FDA FAQ that flagged alternative approaches as potentially inappropriate for BCS 4, Xiao said the current guidance "may reflect the current limitation, but not the permanent restrictions" and argued that a risk‑based, evidence‑focused pathway could broaden acceptable approaches for some products.

Gang Zhao, another panelist, said research is under way to test whether similar risk‑mitigation approaches could apply to high‑risk immediate‑release products. "With scientific evidence support, I think similar risk mitigation strategies can also be used for the high risk IR products," Zhao said, and suggested that, if generics meet defined criteria, some studies might be waived.

Why it matters: BCS (Biopharmaceutics Classification System) categorizations guide when in vivo bioequivalence studies can be waived. Industry interest in alternative approaches for difficult‑to‑classify products is high because waivers can lower development time and costs for generics; FDA panelists stressed the need for product‑specific scientific justification and early engagement with the agency.

The panel did not announce regulatory changes or new guidance; panelists repeatedly recommended early engagement with FDA to confirm study plans and emphasized that proposed alternative approaches would be evaluated case by case. The session closed without a formal vote or policy change.